Literature DB >> 22960427

All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study.

Knut Boe Kielland1, Kjell Skaug, Ellen J Amundsen, Olav Dalgard.   

Abstract

BACKGROUND & AIMS: The course of chronic hepatitis C virus (HCV) in injecting drug users (IDUs) has not been well described. The aim of this study was to compare long-term all-cause and liver-related mortality among anti-HCV positive IDUs with and without persisting HCV infection.
METHODS: A retrospective-prospective controlled cohort design was applied. All IDUs admitted to resident drug treatment (1970-1984) and with available stored sera were screened for anti-HCV antibody. Anti-HCV positive individuals were further tested for the presence of HCV RNA. All-cause and liver-related mortality was compared between HCV RNA positive (n=328) and HCV RNA negative individuals (n=195). The observation was accomplished through register linkage to national registers. Mean observation time was 33 years.
RESULTS: All-cause mortality rate was 1.85 (95% CI 1.62-2.11) per 100 person-years, male 2.11 (95% CI 1.84-2.46), female 1.39 (95% CI 1.07-1.79). Mortality rates were not influenced by persisting HCV infection. Main causes of death were intoxications (45.0%), suicide (9.1%), and accidents (8.2%). Liver disease was the cause of death in 7.5% of deaths among HCV RNA positive subjects. Five of 13 deaths among male IDUs with persisting HCV infection occurring after the age of 50 years were caused by liver disease.
CONCLUSIONS: The all-cause mortality in IDUs is high and with no difference between HCV RNA positive and HCV RNA negative individuals, the first three decades after HCV transmission. However, among IDUs with chronic HCV infection who have survived until 50years of age, HCV infection emerges as the main cause of death.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22960427     DOI: 10.1016/j.jhep.2012.08.024

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  21 in total

1.  Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems.

Authors:  Daniel Fuster; Debbie M Cheng; Emily K Quinn; David Nunes; Richard Saitz; Jeffrey H Samet; Judith I Tsui
Journal:  Addiction       Date:  2013-10-24       Impact factor: 6.526

Review 2.  Treatment of hepatitis C in difficult-to-treat patients.

Authors:  Peter Ferenci
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-04-21       Impact factor: 46.802

Review 3.  Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Authors:  Amber Arain; Geert Robaeys
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

4.  High smoking and low cessation rates among patients in treatment for opioid and other substance use disorders.

Authors:  Endre Dahlen Bjørnestad; John-Kåre Vederhus; Thomas Clausen
Journal:  BMC Psychiatry       Date:  2022-10-19       Impact factor: 4.144

5.  Non-financial barriers in oral health care: a qualitative study of patients receiving opioid maintenance treatment and professionals' experiences.

Authors:  Siv-Elin Leirvaag Carlsen; Katja Isaksen; Lars Thore Fadnes; Ole Jørgen Scheie Lygren; Anne Nordrehaug Åstrøm
Journal:  Subst Abuse Treat Prev Policy       Date:  2021-05-17

6.  Let It "B"? The role of Hepatitis B universal vaccination among italian problematic drug users.

Authors:  Fabio Lugoboni; Raimondo Maria Pavarin; Chiara Resentera; Daniele Gambini
Journal:  Int J Environ Res Public Health       Date:  2015-04-13       Impact factor: 3.390

7.  The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014.

Authors:  Cécile Brouard; Yann Le Strat; Christine Larsen; Marie Jauffret-Roustide; Florence Lot; Josiane Pillonel
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

8.  No strategy to meet the HCV epidemic.

Authors:  Olav Dalgard; Stefan Mauss
Journal:  BMC Infect Dis       Date:  2014-09-19       Impact factor: 3.090

Review 9.  Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.

Authors:  Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

10.  Predictors of liver-related death among people who inject drugs in Vancouver, Canada: a 15-year prospective cohort study.

Authors:  Kanna Hayashi; Michael-John Milloy; Evan Wood; Huiru Dong; Julio S G Montaner; Thomas Kerr
Journal:  J Int AIDS Soc       Date:  2014-11-10       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.